## POP Biotechnologies Awarded $2.46M NIH Grant for Alzheimer's Immunotherapy **October 1, 2025** POP Biotechnologies, Inc. (POP BIO), has been awarded a $2.46M USD grant by the National Institutes of Health (NIH) to pursue development of a “mosaic” active immunotherapy against Alzheimer’s disease (AD). [Read More](/content/news/p2-nih-grant-for-alzheimers-immunotherapy/index.html) ## POP BIO and CEPI announce collaboration for faster responses to Disease X **July 24, 2025** POP BIO announces award of $1.5M award from CEPI to advance SNAP platform into development of a vaccine against severe fever with thrombocytopenia syndrome (SFTS) [Read More](/content/news/popbio-and-cepi-announce-collaboration/index.html) ## POP BIO Announces Vaccine Concept Targeting Avian Influenza H5N1 Clade 2.3.4.4b **April 17, 2025** [Read More](/content/news/h5n1-bird-flu/index.html) ## POP BIO Cancer Vaccine Concept Accepted into NCI Nanotechnology Characterization Program **February 26, 2025** POP Biotechnologies accepted into the NCI Nanotechnology Characterization Laboratory for evaluation of an ultra-potent cancer vaccine system for short MHC-I restricted synthetic peptides [Read More](/content/news/pop-biotechnologies-accepted-into-nanotechnology-characterization-laboratory-assay-cascade-characterization-program/index.html) ## POP BIO awarded $2.84M Phase II SBIR for seasonal influenza vaccine development **November 26, 2024** POP Biotechnologies Inc. (POP BIO) received a $2.84M Phase II SBIR under award number 1R44AI181479-01, supported by the National Institute of Allergies and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to pursue the development of a unique vaccine approach against seasonal influenza. [Read More](/content/news/pop-bio-awarded-2-84m-phase-ii-sbir-for-seasonal-influenza-vaccine-development/index.html) ## POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP™ **September 27, 2024** BUFFALO, N.Y., September 27, 2024 - POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, is pleased to announce the publication of positive findings in a peer-reviewed paper in the Journal of Medical Virology entitled “Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines”. [Read More](/content/news/pop-biotechnologies-announces-phase-3/index.html) ## POP BIO announces findings for an Alzheimer’s Disease polyvalent peptide immunotherapy **September 13, 2024** POP Biotechnologies has announced positive results for their pentavalent peptide vaccine targeting Alzheimer’s Disease, published in Brain Behavior and Immunity. The vaccine, utilizing POP BIO’s SNAP™ technology, demonstrated efficacy in mice by targeting multiple epitopes of amyloid-β and tau proteins, showing potential for treating early-stage AD. The vaccine is now advancing toward clinical trials through EuPOP Life Sciences, a joint venture with EuBiologics. [Read More](/content/news/pop-bio-alzheimers-disease-polyvalent-peptide-immunotherapy/index.html) ## POP BIO and FunPep Announce Collaboration for Antibody-Inducing Peptide Therapy **August 21, 2024** POP Biotechnologies announces the furtherance of research with FunPep. Advanced preclinical testing of antibody-inducing peptides will be carried out. [Read More](/content/news/pop-bio-and-funpep-announce-collaboration-for-antibody-inducing-peptide-therapy/index.html) ## POP BIO and EuBiologics’ Shingles Vaccine Enters Phase 1 Clinical Trials **August 7, 2024** POP Biotechnologies announces the commencement of dosing of the shingles vaccine “EuHZV” in collaboration with EuBiologics in a Phase 1 clinical study in Korea [Read More](/content/news/pop-bio-and-eubiologics-shingles-vaccine-enters-phase-1-clinical-trials/index.html) ## SNAP Platform Enters Phase I Clinical Studies for RSV **May 10, 2024** EuBiologics co.,Ltd has started Phase 1 testing of EuRSV, a next-generation RSV vaccine. This is now the second vaccine (after EuCorVac-19) to enter human testing based on University at Buffalo and POP Biotechnologies’ SNAP vaccine adjuvant system. [Read More](/content/news/snap-platform-enters-phase-i-clinical-studies-for-rsv/index.html) ## Janssen Vaccines collaboration with POP BIO’s SNAP vaccine platform results published in Nature Communications **April 12, 2024** POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces the publication of new data involving a SNAP-based C HIV-1 Env vaccine available [Read More](/content/news/janssen-vaccines-collaboration-with-pop-bios-snap-vaccine-platform-results-published-in-nature-communications/index.html) ## POP BIO and EuBiologics’ EuCorVac-19 COVID-19 vaccine hits target in Phase 3 trial **June 23, 2023** POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19 [Read More](/content/news/pop-bio-and-eubiologics-eucorvac-19-covid-19-vaccine-hits-target-in-phase-3-trial/index.html) ## POP Biotechnologies awarded $2M NIH-NCI Phase II STTR in collaboration with Roswell Park **February 1, 2023** POP Biotechnologies awarded $2M NIH-NCI Phase II STTR in collaboration with Roswell Park [Read More](/content/news/pop-biotechnologies-awarded-2m-nih-nci-phase-ii-sttr-in-collaboration-with-roswell-park/index.html) ## POP Biotechnologies’ SNAP Vaccine Platform Enters Large Scale Clinical Trials for COVID-19 **November 30, 2022** POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics from the Ministry of Food and Drug Safety in South Korea. [Read More](/content/news/pop-biotechnologies-snap-vaccine-platform-enters-large-scale-clinical-trials-for-covid-19/index.html) ## POP Biotechnologies’ SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19 **November 30, 2022** POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics from the Ministry of Food and Drug Safety in South Korea. [Read More](/content/news/pop-biotechnologies-snap-vaccine-system-safe-and-effective-in-a-phase-ii-clinical-trial-for-covid-19/index.html)